Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sofie Verbeke is active.

Publication


Featured researches published by Sofie Verbeke.


Virchows Archiv | 2017

Whipple’s disease in granulomatous disguise: a challenging diagnosis with many histopathological pitfalls

Mieke Van Bockstal; Anne Hoorens; Filip Van den Bosch; David Creytens; Sofie Verbeke; Jo Van Dorpe

Whipple’s disease is a rare systemic illness caused by Tropheryma whipplei, a Gram-positive bacterium. Despite its abundant natural prevalence and reports on frequent asymptomatic carriage of T. whipplei, Whipple’s disease has an estimated annual incidence between only one and six per 10 million populations. This disease predominantly affects middle-aged white males [5, 6, 9]. Specific HLA constellations predispose to the development of Whipple’s disease by hampering the protective immune response that occurs in most infected individuals [5]. Impaired function of intestinal macrophages prevents the degradation of T. whipplei and results in massive accumulation of macrophages, laden with this intracellular pathogen, in the lamina propria of the small intestine [6]. Early reports on Whipple’s disease describe a Bclassic^ form, characterized by gastrointestinal symptoms such as diarrhea, malabsorption, abdominal pain, and weight loss [10]. Occasional case reports in the past decades have broadened our view on the clinical presentation, since they showed that Whipple’s disease can mimic many other conditions. Therefore, diagnosis is often delayed [1, 3, 8, 12]. Here, we describe an atypical presentation of Whipple’s disease, concerning a man who initially presented with cervical lymphadenopathy only. At first, he was misdiagnosed with sarcoidosis, a mimic of Whipple’s disease. Several biopsies were performed during the diagnostic process. Here, we discuss potential diagnostic pitfalls based on the obtained histopathological images.


Histopathology | 2018

Some diffuse large B-cell lymphomas (DLBCLs) present with clone-dependent TTF-1 positivity.

Mieke Van Bockstal; Alessandra Camboni; Elly De Vlieghere; Frédéric De Ryck; Ann-Sophie Candaele; Sofie Geenen; Lies Vandemaele; Olivier De Wever; Louis Libbrecht; Sofie Verbeke; Jo Van Dorpe

Sir: Thyroid-specific transcription factor 1 (TTF-1) is a transcription factor encoded by the NK2 homeobox 1 (NKX2-1) gene, located on chromosome 14. Because of its restricted expression pattern, TTF-1 used to be regarded as a specific marker for tumours originating in the thyroid and the lung, thereby facilitating investigations of cancers of unknown primary (CUPs). Immunohistochemistry for TTF-1 can differentiate primary pulmonary adenocarcinomas from lung metastases of non-pulmonary adenocarcinomas, and can distinguish solid pulmonary adenocarcinomas from squamous cell carcinomas of the lung. Increasing evidence indicates that TTF-1 expression can also occur in adenocarcinomas of non-pulmonary origin, such as the colon, prostate, endometrium, cervix and breast. This phenomenon constitutes a diagnostic challenge, as it might result in misdiagnosis of (metastatic) primary pulmonary adenocarcinoma. We recently encountered TTF-1 expression in a poorly differentiated neoplasm of uncertain origin, located subcutaneously on the thorax of a man with a history of pulmonary adenocarcinoma. Haematoxylin and eosin staining showed a poorly differentiated discohesive large cell neoplasm with pleomorphic vesicular nuclei and numerous mitotic figures. Glandular or squamous differentiation were lacking. Initial immunohistochemistry included markers for S100, TTF1 (SPT24 clone), broad-spectrum cytokeratin (AE1/AE3) and CD45 (Figure 1). The neoplasm was negative for S100 and cytokeratins, ruling out metastatic melanoma and carcinoma, respectively. Despite diffuse positive staining for


Histopathology | 2018

Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial interobserver concordance

Mieke Van Bockstal; Marcella M. Baldewijns; Cecile Colpaert; Hélène Dano; Giuseppe Floris; Christine Galant; Kathleen Lambein; Dieter Peeters; Sofie Van Renterghem; Anne-Sophie Van Rompuy; Sofie Verbeke; Stephanie Verschuere; Jo Van Dorpe

Robust prognostic markers for ductal carcinoma in situ (DCIS) of the breast require high reproducibility and thus low interobserver variability. The aim of this study was to compare interobserver variability among 13 pathologists, in order to enable the identification of robust histopathological characteristics.


British Journal of Surgery | 2018

Routine histopathological examination after female-to-male gender-confirming mastectomy: Routine histopathological examination after gender-confirming mastectomy

S. M. J. Van Renterghem; J. Van Dorpe; Stan Monstrey; Justine Defreyne; K. E. Y. Claes; Marleen Praet; Sofie Verbeke; Guy T'Sjoen; M. Van Bockstal

The number of transmen seeking gender‐confirming surgery has risen steadily throughout the last decade. Pathologists are increasingly confronted with transmale mastectomy specimens. It is not clear whether routine histopathological examination is useful. This study explored the possible benefit of routine investigation through detailed description of lesions encountered in mastectomy specimens after female‐to‐male gender‐confirming surgery.


Journal of Translational Medicine | 2017

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma : evaluation of safety and clinical and immunologic response

Nora Sundahl; Katrien De Wolf; Sylvie Rottey; Karel Decaestecker; Daan De Maeseneer; Annabel Meireson; Els Goetghebeur; Valérie Fonteyne; Sofie Verbeke; Pieter De Visschere; Dries Reynders; Mireille Van Gele; Lieve Brochez; Piet Ost


Urologic Oncology-seminars and Original Investigations | 2018

Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial

Sarah Buelens; Filip Poelaert; Bert Dhondt; Valérie Fonteyne; Pieter De Visschere; Piet Ost; Sofie Verbeke; Geert Villeirs; Kathia De Man; Sylvie Rottey; Karel Decaestecker; Nicolaas Lumen


Radiotherapy and Oncology | 2018

OC-0682: Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma

Nora Sundahl; Sylvie Rottey; Karel Decaestecker; P. De Visschere; Daan De Maeseneer; Dries Reynders; Annabel Meireson; Els Goetghebeur; Valérie Fonteyne; Sofie Verbeke; Lieve Brochez; Piet Ost


Pathology | 2018

Malignant peripheral nerve sheath tumour with heterologous liposarcomatous differentiation : case report and review of the literature

Carole Van Haverbeke; Liesbeth Ferdinande; Sofie Verbeke; Jo Van Dorpe; David Creytens


Virchows Archiv | 2017

TTF-1 expression in diffuse large B-cell lymphoma : an unusual but tricky phenomenon

Alessandra Camboni; Mieke Van Bockstal; Louis Libbrecht; Ann-Sophie Candaele; Sofie Verbeke; Jo Van Dorpe


Virchows Archiv | 2017

Histopathology of transgender breast specimens: Expect the unexpected!

Sofie Van Renterghem; Jo Van Dorpe; Guy T'Sjoen; Stan Monstrey; Sofie Verbeke; Mieke Van Bockstal; Justine Defreyne; Karel Claes; Marleen Praet

Collaboration


Dive into the Sofie Verbeke's collaboration.

Top Co-Authors

Avatar

Jo Van Dorpe

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mieke Van Bockstal

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Piet Ost

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar

Sylvie Rottey

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Louis Libbrecht

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge